Monday, March 11, 1996
Biotech in Germany
The Max Planck ventures
Among German research institutions, the Max Planck Society has been one of the first to pursue the licensing of its technology for commercial development.
The society's most visible commercial venture is its role in co-founding Sugen Inc. (SUGN, Redwood City, Calif.) based on work by Axel Ullrich in receptor tyrosine kinases and receptor tyrosine phosphatases. The company was the first in